Integra Lifesciences Holdings (IART) Accounts Payables (2009 - 2026)

Integra Lifesciences Holdings has disclosed Accounts Payables across 18 years of filings, most recently posting $82.6 million for Q2 2026.

• In Q2 2026, Accounts Payables fell 10.99% year-over-year to $82.6 million; the TTM figure through Jun 2026 stood at $82.6 million (down 10.99% YoY), while the FY2025 annual figure was $95.7 million, up 16.03% from the prior year.
• Accounts Payables came in at $82.6 million for Q2 2026 at Integra Lifesciences Holdings, down from $87.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $112.8 million in Q1 2023 to a low of $69.5 million in Q2 2022.
• Average Accounts Payables over 5 years is $91.3 million, with a median of $92.3 million recorded in 2023.
• Year-over-year, Accounts Payables surged 65.11% in 2022 and decreased 16.98% in 2024.
• Over 5 years, Accounts Payables stood at $102.1 million in 2022, then slipped by 9.57% to $92.3 million in 2023, then retreated by 10.64% to $82.5 million in 2024, then advanced by 16.03% to $95.7 million in 2025, then dropped by 13.67% to $82.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $82.6 million in Q2 2026, $87.9 million in Q1 2026, and $95.7 million in Q4 2025.